If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
The first 7-Eleven store in Denmark was opened at Østerbro in Copenhagen on September 14, 1993. There are 185 stores, mostly in Copenhagen, Aarhus, Aalborg, and Odense, including two stores at Copenhagen Central Station. In Denmark, 7-Eleven had an agreement with Shell, with a nationwide network of Shell/7-Eleven service stations. This ended in 2024 when the national franchise operator Reitan Danmark did not renew the agreement and instead used their own brand of service station Uno-X. 7-Eleven also have an agreement with the Danish railway company DSB to have 7-Eleven stores at most S-train stations and other train stations. In 2022, 7-Eleven in Denmark suffered a widespread ransomware attack that caused all stores to temporarily close. 7-Eleven did not comply with the attacker's demands. No customer data was compromised in the attack. The three biggest 7-Eleven stores in terms of revenue in the world, are all located in Denmark. The top two stores are both located at Copenhagen Central Station and the third are located at Copenhagen Airport beyond security.
By the middle of 1982, the Soviet Union alone maintained major mycological herbaria across 25 research institutions or museums and 11 universities, academies, and institutes, together preserving more than one million fungal specimens, including over 5,000 type specimens. The transition from morphology-based systematics to phylogenetics in the 1980s and 1990s further changed the role of historical collections, as scientists began extracting DNA from specimens collected more than a century earlier. Historical plant herbaria as well as dedicated mycological collections have also yielded valuable fungal and oomycete records when older specimens were re-examined for disease symptoms that were not the original focus of collection.
In June 2020, Lilly announced that, in collaboration with Vancouver-based AbCellera, it had begun the world's first study of a potential monoclonal antibody treatment for treatment of COVID-19, with a Phase 1 trial of LY-CoV555. By August 2020, the challenging aspects of running a clinical trial in a long-term care facility during a pandemic prompted Lilly to create the first of many customized recreational vehicles into mobile research units (MRU) to meet people where they were and support mobile labs and clinical trial material preparation. A trailer truck could escort the MRU with supplies to create an on-site infusion clinic. Lilly deployed the mobile research unit fleet in response to outbreaks of the virus at long-term care facilities across the US. In September 2020, Amgen partnered with Lilly to manufacture COVID-19 antibody therapies. In October 2020, Lilly announced that its cocktail was effective and that it had filed with the FDA for an emergency use authorization (EUA). The same day, Regeneron Pharmaceuticals also filed for an EUA for its own monoclonal antibody treatment. The same month, Lilly announced it would acquire Disarm Therapeutics and its experimental treatments for axonal degeneration, via SARM1 inhibitors, for $135 million plus up to another $1.225 billion based on regulatory and commercial milestones.
The hypothalamic–pituitary–somatotropic axis (HPS axis), or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone (GH; somatotropin) from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 (IGF-1; somatomedin-1) production by GH in tissues such as, namely, the liver. Other hypothalamic–pituitary hormones such as growth hormone-releasing hormone (GHRH; somatocrinin), growth hormone-inhibiting hormone (GHIH; somatostatin), and ghrelin (GHS) are involved in the control of GH secretion from the pituitary gland. The HPS axis is involved in postnatal human growth. Individuals with growth hormone deficiency or Laron syndrome (GHRTooltip growth hormone receptor insensitivity) show symptoms like short stature, dwarfism and obesity, but are also protected from some forms of cancer. Conversely, acromegaly and gigantism are conditions of GH and IGF-1 excess usually due to a pituitary tumor, and are characterized by overgrowth and tall stature.
Pheromone Endorphins Anaphrodisiac Date rape drug Entactogen Food and sexuality Fork Me, Spoon Me, 2006 book Hypersexuality Hypoactive sexual desire disorder List of investigational sexual dysfunction drugs Love potion Phytoestrogen Phytoandrogen Androgens Estrogens Viagra Vyleesi
Sources: en.wikipedia.org
=== Education === Since 2019, the HISP Centre has worked with six countries to pilot DHIS2 as an Education Management Information System (EMIS), with financial support from NORAD and GPE/KIX. This use case adapts the core DHIS2 functionality and data model to the education sector for such purposes as student and teacher records, school report cards, and resource allocation.
==== Information about donor ==== In the United States, sperm banks maintain lists of donors which provide basic information about the donor such as racial origin, skin color, height, weight, color of eyes, and blood group. Qualities that potential recipients typically prefer in donors include the donors being tall, college educated, and with a consistently high sperm count. A review came to the result that 68% of donors had given information to the clinical staff regarding physical characteristics and education but only 16% had provided additional information such as hereditary aptitudes and temperament or character.
===== MeSH D08.811.913.555 – one-carbon group transferases (EC 2.1) ===== MeSH D08.811.913.555.150 – amidinotransferases MeSH D08.811.913.555.275 – carboxyl and carbamoyl transferases MeSH D08.811.913.555.275.200 – aspartate carbamoyltransferase MeSH D08.811.913.555.275.600 – ornithine carbamoyltransferase MeSH D08.811.913.555.400 – hydroxymethyl and formyl transferases MeSH D08.811.913.555.400.100 – aminomethyltransferase MeSH D08.811.913.555.400.300 – glutamate formimidoyltransferase MeSH D08.811.913.555.400.500 – glycine hydroxymethyltransferase MeSH D08.811.913.555.400.625 – phosphoribosylaminoimidazolecarboxamide formyltransferase MeSH D08.811.913.555.400.750 – phosphoribosylglycinamide formyltransferase MeSH D08.811.913.555.500 – methyltransferases MeSH D08.811.913.555.500.100 – acetylserotonin n-methyltransferase MeSH D08.811.913.555.500.175 – betaine-homocysteine S-methyltransferase MeSH D08.811.913.555.500.250 – catechol O-methyltransferase MeSH D08.811.913.555.500.350 – dna modification methylases MeSH D08.811.913.555.500.350.500 – dna (cytosine-5-)-methyltransferase MeSH D08.811.913.555.500.350.700 – site-specific dna-methyltransferase (adenine-specific) MeSH D08.811.913.555.500.350.850 – site-specific dna methyltransferase (cytosine-specific) MeSH D08.811.913.555.500.387 – glycine N-methyltransferase MeSH D08.811.913.555.500.425 – guanidinoacetate N-methyltransferase MeSH D08.811.913.555.500.500 – histamine N-methyltransferase MeSH D08.811.913.555.500.625 – homocysteine S-methyltransferase MeSH D08.811.913.555.500.645 – 5-methyltetrahydrofolate-homocysteine s-methyltransferase MeSH D08.811.913.555.500.650 – nicotinamide N-methyltransferase MeSH D08.811.913.555.500.700 – phenylethanolamine N-methyltransferase MeSH D08.811.913.555.500.710 – phosphatidyl-N-methylethanolamine N-methyltransferase MeSH D08.811.913.555.500.712 – phosphatidylethanolamine N-methyltransferase MeSH D08.811.913.555.500.800 – protein methyltransferases MeSH D08.811.913.555.500.800.400 – histone-lysine n-methyltransferase MeSH D08.811.913.555.500.800.650 – o-6-methylguanine-DNA methyltransferase MeSH D08.811.913.555.500.800.750 – protein-arginine n-methyltransferase MeSH D08.811.913.555.500.800.800 – protein o-methyltransferase MeSH D08.811.913.555.500.800.800.700 – protein d-aspartate-l-isoaspartate methyltransferase MeSH D08.811.913.555.500.862 – thymidylate synthase MeSH D08.811.913.555.500.925 – trna methyltransferases
== Protein == Seryl-tRNA synthetase is made up of 514 amino acid residues as weighs 58,777 Da. It exists as a homodimer of two identical subunits, with the tRNA molecule binding across the dimer by similarity. It has two distinct domains:
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.